Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,094,959
  • Shares Outstanding, K 33,241
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,330 K
  • 60-Month Beta 0.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.38
  • Low Estimate -0.42
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -53.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.50 +25.60%
on 09/01/20
37.88 -8.82%
on 09/18/20
+5.57 (+19.23%)
since 08/25/20
3-Month
22.10 +56.29%
on 07/14/20
37.88 -8.82%
on 09/18/20
+11.01 (+46.79%)
since 06/25/20
52-Week
15.82 +118.33%
on 03/13/20
37.88 -8.82%
on 09/18/20
+11.75 (+51.56%)
since 09/25/19

Most Recent Stories

More News
Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the...

TCRR : 18.53 (+2.66%)
BDTX : 29.65 (+10.14%)
DVA : 83.90 (+2.87%)
RGLS : 0.4800 (+4.14%)
STOK : 34.54 (+4.86%)
Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Invitae Corporation (NYSE: NVTA) announced that Biogen (NASDAQ: BIIB), Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics...

PTCT : 46.60 (+0.47%)
BMRN : 77.39 (+1.06%)
BIIB : 273.28 (+1.20%)
NVTA : 44.67 (+4.59%)
STOK : 34.54 (+4.86%)
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

Stoke Therapeutics, Inc.(Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression,...

JPM : 93.47 (+0.87%)
STOK : 34.54 (+4.86%)
Stoke Therapeutics, Inc. (STOK) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Stoke Therapeutics, Inc. (STOK).

STOK : 34.54 (+4.86%)
Can The Uptrend Continue for Stoke Therapeutics?

As of late, it has definitely been a great time to be an investor Stoke Therapeutics.

STOK : 34.54 (+4.86%)
Will Stoke Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Stoke Therapeutics.

STOK : 34.54 (+4.86%)
Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced...

JPM : 93.47 (+0.87%)
STOK : 34.54 (+4.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Trade STOK with:

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

2nd Resistance Point 36.12
1st Resistance Point 35.33
Last Price 34.54
1st Support Level 33.19
2nd Support Level 31.84

See More

52-Week High 37.88
Last Price 34.54
Fibonacci 61.8% 29.45
Fibonacci 50% 26.85
Fibonacci 38.2% 24.25
52-Week Low 15.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar